Akebia Therapeutics (FRA:AX9) Growth Rank: 1 (As of Aug. 03, 2026) — 80% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX9 Akebia Therapeutics Inc FRA:AX9
54 GF Score
Price €1.15
GF Value €1.05
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Growth Rank?

Akebia Therapeutics FRA:AX9 +6.85% 54 Growth Rank is 1 as of Aug. 03, 2026, which is 80% below its 10-year median of 5.00. GuruFocus rates FRA:AX9 with a GF Score™ of 54/100 and a GF Value™ of €1.05 (Fairly Valued). The stock has 5 warning signs investors should review.

Akebia Therapeutics has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Akebia Therapeutics Growth Rank Related Terms

FRA:AX9 vs ORGO, EBS, TKNO: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Growth Rank falls into.


FRA:AX9
54GF Score
Akebia Therapeutics Inc FRA:AX9
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Akebia Therapeutics (FRA:AX9) has a Growth Rank of 1 as of Aug. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Akebia Therapeutics and its competitors. This is 80% below median its historical median of 5.00. Over the past decade, Akebia Therapeutics' Growth Rank has ranged from 1.00 to 8.00.
Is Akebia Therapeutics' Growth Rank too high?
Akebia Therapeutics' current Growth Rank of 1 is 80% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, Akebia Therapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Growth Rank compare to ORGO and EBS?
Akebia Therapeutics' Growth Rank of 1 can be compared against companies in the Drug Manufacturers industry. Historically, Akebia Therapeutics' own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Growth Rank is 1, which is 80% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.05, compared to a current price of €1.15 — trading 9.2% above its estimated fair value. The current Growth Rank is 1, which is 80% below median its 10-year median of 5.00. Akebia Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Growth Rank is 1 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.15 is trading 9.2% above its estimated GF Value™ of €1.05. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for FRA:AX9:

  • Growth Rank: 1 (80% below median its 10-year median of 5.00)
  • GF Value™: €1.05 vs. price of €1.15 (9.2% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USAAX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
54GF Score

Get the complete analysis for FRA:AX9

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.15
Price
€1.05
GF Value